(Q46010734)

18 December 2017

title

Discovery and structure-activity relationship studies of a unique class of HIV-1 integrase inhibitors. (English)

1 reference

18 December 2017

author name string

Raveendra Dayam

series ordinal

1

1 reference

18 December 2017

Tino Sanchez

series ordinal

2

1 reference

18 December 2017

Nouri Neamati

series ordinal

3

1 reference

18 December 2017

publication date

1 February 2006

1 reference

18 December 2017

published in

ChemMedChem

1 reference

18 December 2017

volume

1

1 reference

18 December 2017

issue

2

1 reference

18 December 2017

page(s)

238-244

1 reference

18 December 2017

https://api.crossref.org/works/10.1002%2FCMDC.200500018

1 reference

7 January 2021

Strategies in the design of antiviral drugs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

New approaches toward anti-HIV chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Small-molecule HIV-1 integrase inhibitors: the 2001-2002 update

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Integrase inhibitors to treat HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Structure-based HIV-1 integrase inhibitor design: a future perspective

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Potent inhibitors of human immunodeficiency virus type 1 integrase: identification of a novel four-point pharmacophore and tetracyclines as novel inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Discovery of HIV-1 integrase inhibitors by pharmacophore searching.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Efficient 3D database screening for novel HIV-1 IN inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Beta-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Developing a dynamic pharmacophore model for HIV-1 integrase.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Dynamic receptor-based pharmacophore model development and its application in designing novel HIV-1 integrase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide).

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation. A pilot study in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Suppression of HIV-1 infection in linomide-treated SCID-hu-PBL mice

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Drug-like properties and the causes of poor solubility and poor permeability

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Polar molecular surface properties predict the intestinal absorption of drugs in humans.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Prediction of intestinal permeability

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Development and validation of a genetic algorithm for flexible docking

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

A new test set for validating predictions of protein-ligand interaction.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200500018

7 January 2021

Identifiers

DOI

10.1002/CMDC.200500018

1 reference

18 December 2017

1 reference

18 December 2017